Qurient Demonstrates Efficacy and Safety of Mocaciclib Phase 1 Across Breast, Prostate and Pancreatic Cancers
Predicted impact: Low
Phase 1 data already reported via ESMO unveiling within the last 14 days; no new size.
Qurient큐리언트
115180 · KOSDAQ · ₩115180 · 큐리언트
₩16,590▼ ₩1,240 (6.95%)End-of-day · Oct 30, 2026 · End-of-day prices.
[Today's Market Calendar] Curient, MH Ethanol, Duobac and Others
Predicted impact: Low
Curient unveils Phase 1 data for 'mocaciclib' at ESMO: "Worked in terminal cancer patients who failed existing treatments"
Predicted impact: Medium
Phase 1 cancer data at ESMO; tiny revenue base, but a rights offering is pending, so data matters.
Inventage Lab and Qurient Surge; Hanmi Pharm Plunges 10% as Eppe Prices Are Revealed [Bio Market Check]
Predicted impact: Low· Actual: −2.1% vs sector, volume 0.7× normal (5 trading days)
Market-wrap piece on a sector rebound tied to a peer's price news; no company-specific event disclosed.
Qurient Teams Up with Lonza, Faces Test in Monetizing Anticancer Drug Candidate
Predicted impact: Medium· Actual: −8.9% vs sector, volume 1.1× normal (5 trading days)
Licensing and co-commercialization deal with Lonza; size undisclosed, so impact is uncertain.
Qurient Partners with Lonza, Aims to Monetize Dual ADC
Predicted impact: Low· Actual: −8.9% vs sector, volume 1.1× normal (5 trading days)
Same Lonza ADC partnership already reported in the last 14 days, lowered one level.
Curiant and Lonza Unveil Dual-Payload ADC Platform at UK's ELRIG, "Accelerating Commercialization"
Predicted impact: Low· Actual: −7.7% vs sector, volume 1.3× normal (5 trading days)
Platform unveiling repeats the Lonza co-commercialization deal already in the last 14 days.
Dongu Bio "Bio Investments Bear Fruit… Results from Curient, D&D and Novacell Take Shape"
Predicted impact: Low· Actual: −4.5% vs sector, volume 1.8× normal (5 trading days)
Curient ADC deal with Lonza already reported in past 14 days; no size disclosed.
Curient rises 8% on ADC co-commercialization deal with Lonza [Why Bio]
Predicted impact: Medium· Actual: −4.5% vs sector, volume 1.8× normal (5 trading days)
Licensing and co-commercialization deal with Lonza; value undisclosed but shares rose 8%.
Curiient and Lonza unveil dual-payload ADC platform, step up global technology transfer efforts
Predicted impact: Low· Actual: −4.5% vs sector, volume 1.8× normal (5 trading days)
Platform unveiling with a partner; no deal size disclosed.
Curient to pursue third-party technology transfer as early as this year [Why Bio]
Predicted impact: Low· Actual: −4.5% vs sector, volume 1.8× normal (5 trading days)
Possible technology transfer planned; no deal size disclosed yet.
Also known as: Qurient / 큐리언트 / 115180 / KRX:115180
Source: KRX statistical information